Is MSGS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Franchise scarcity, with revenue (ttm, through june 2026) at ~$1.15 billion. The bear case rests on the Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management. Analysts covering it are spread from $450.00 to $584.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $450.00, +17.1% from the $384.39 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Franchise scarcity. There are 30 NBA teams and 32 NHL teams, and the two in the largest US media market almost never change hands. The most optimistic analyst target on MSGS is $584.00, +51.9% from the $384.39 price. That figure is only reachable if this thesis works close to its best case.

The Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management. The spin-off has been approved and scheduled, so the main uncertainty has moved from whether it happens to how the two pieces trade: the Rangers company in particular will be a smaller, thinner stock, and nothing in the separation changes Dolan control of either. The company generates little in the way of reported profit (trailing twelve-month net income of only ~$8 million on ~$1.15 billion of revenue as of June 2026, after a ~$22 million loss in fiscal 2025), so there is no earnings support underneath the price if franchise appraisals stop rising. Player compensation, collective bargaining outcomes and luxury-tax structures in both leagues can raise costs faster than revenue, and local media rights remain the softest part of the model. Debt of ~$1.16 billion sits against ~$165 million of cash, and how it is divided between the two companies matters to each one's equity value. Finally, with roughly ~24 million shares outstanding, the float is small and the stock can move sharply on transaction headlines in either direction. The most pessimistic published target is $450.00, +17.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Owner of the New York Knicks and Rangers; franchise values sit well above the market cap under Dolan family control.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Franchise scarcity) stalling in the reported numbers rather than in the narrative, the risk above (the Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

MSGS owns the New York Knicks (NBA) and the New York Rangers (NHL), plus their development-league affiliates and a sports performance business. It does not own the Madison Square Garden arena itself, which sits inside MSG Entertainment, and it does not own Sphere. The teams pay to use the arena under long-term arrangements with the separately listed entertainment company.

Sportico values the Knicks around ~$9.85 billion and the Rangers around ~$3.65 billion, a combined ~$13.5 billion, against an equity value near ~$9.6 billion on October 16, 2026. The gap reflects ~$1.16 billion of company debt, the fact that no minority shareholder can force a sale, and the Dolan family's voting control. Appraised values assume a control transaction that public holders cannot initiate.

MSGS has Class A shares with one vote each, which is what trades on the NYSE under MSGS, and Class B shares with ten votes each held almost entirely by the Dolan family. Class B holders also elect 75% of the board while Class A holders elect the remaining 25%. The practical effect is that outside shareholders have economic exposure without meaningful governance influence.